Clinical Trial: NCT05364073
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | ArriVent BioPharma, Inc. |
| Information Provided By: | ArriVent BioPharma, Inc. |
| Last Update Posted: | 2026-11-12 |
Study Overview
Brief Summary
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Official Title
Conditions
Intervention / Treatment
- Drug: Furmonertinib
- Drug: Furmonertinib
- Drug: Furmonertinib
- Drug: Furmonertinib
- Drug: Furmonertinib
Other Study ID Numbers
- FURMO-002
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | ArriVent BioPharma, Inc. |
| Information Provided By: | ArriVent BioPharma, Inc. |
| Last Update Posted: | 2026-11-12 |
Study Overview
Brief Summary
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Official Title
Conditions
Intervention / Treatment
- Drug: Furmonertinib
- Drug: Furmonertinib
- Drug: Furmonertinib
- Drug: Furmonertinib
- Drug: Furmonertinib
Other Study ID Numbers
- FURMO-002